Theravance Biopharma Inc (TBPH) was Initiated by Leerink Partners to “Outperform” and the brokerage firm has set the Price Target at $26. Leerink Partners advised their investors in a research report released on May 12, 2016.
Many Wall Street Analysts have commented on Theravance Biopharma Inc. Theravance Biopharma Inc was Downgraded by BofA/Merrill to ” Neutral” on May 5, 2016.
Theravance Biopharma Inc opened for trading at $17.25 and hit $19.42 on the upside on Tuesday, eventually ending the session at $18.86, with a gain of 1.23% or 0.23 points. The heightened volatility saw the trading volume jump to 8,69,218 shares. Company has a market cap of $725 M.
In a different news, on Aug 18, 2015, Junning Lee (Sr. VP, Technical Operations) purchased 9,000 shares at $12.90 per share price. According to the SEC, on Aug 18, 2015, Burton G Malkiel (director) purchased 10,000 shares at $12.92 per share price. On Aug 17, 2015, Renee D Gala (CFO) purchased 10,000 shares at $12.18 per share price, according to the Form-4 filing with the securities and exchange commission.
Theravance Biopharma Inc. (Theravance Biopharma) is a biopharmaceutical company. The Company is engaged to create value from a diverse set of assets: an approved product; a development pipeline of mid- and late-stage assets and a productive research platform designed for long-term growth. VIBATIV (telavancin) its commercial product is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily oral treatment for opioid-induced constipation (OIC). Its earlier-stage clinical assets represent approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease.